J&J expects to file for approval of 11 drugs by 2015

05/26/2011 | Wall Street Journal, The · Reuters

Johnson & Johnson intends to submit 11 treatments for regulatory approval by 2015, the health care giant told analysts and investors. Among them are Alzheimer's disease medicine bapineuzumab and type 2 diabetes drug canagliflozin. "We are returning to growth, and we expect to outpace market growth," said Sheri McCoy, vice chairwoman and executive-committee member.

View Full Article in:

Wall Street Journal, The · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director of Product Planning Development; Market Planning, Innovation
Blue Cross Blue Shield of Massachusetts
Quincy , MA
Director, Payer Marketing
Avalere Health
Washington, DC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX